Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

Abstract

Aberrant activation of the epidermal growth factor receptor (EGFR) is a driving force for cancer growth in a subgroup of non-small cell lung cancer patients. These patients can be identified by the presence of activating EGFR mutations. Currently three generations of EGFR-tyrosine kinase inhibitors (TKIs) have been approved by the Food and Drug Administration and European Medicine Agency. This paper reviews the structure of EGFR and the downstream signaling pathways of EGFR and describes the mechanisms of intrinsic and acquired resistance against EGFR-TKIs. These mechanisms include secondary or tertiary mutations in EGFR, the activation of bypassing signaling pathways or a histological transformation to small cell lung cancer. Moreover, drug efflux transporters will affect the cellular accumulation of EGFR-TKIs and penetration of the first generation of EGFR-TKI into the brain. Lysosomal sequestration of some EGFR-TKIs may also prevent the drugs to reach their target. In conclusion, resistance to EGFR-TKIs is multifactorial, including primary and acquired mutations in the EGFR gene, activation of bypassing pathways and limited uptake of drugs in the cells or target tissues. More pharmacological studies are needed in order to develop new specific compounds targeted to overcome new resistance mechanisms in order to enable a personalized treatment approach.

Keywords

Epidermal growth factor receptor / non-small cell lung cancer / resistance / EGFR-tyrosine kinase inhibitors / erlotinib / gefitinib / afatinib / osimertinib / rociletinib

References

[1] Novello S,Califano R,Ekman S,Kerr K,Reck M,Simo GV,Peters S.Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up..Ann Oncol2016;27:V1-27

[2] Oda K,Funahashi A.A comprehensive pathway map of epidermal growth factor receptor signaling..Mol Syst Biol2005;1:2005.0010 PMCID:PMC1681468

[3] Yun CH,Li Y,Greulich H,Eck MJ.Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity..Cancer Cell2007;11:217-27 PMCID:PMC1939942

[4] Recondo G,Olaussen KA,Friboulet L.Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?.Nat Rev Clin Oncol2018;

[5] Pao W,Zakowski M,Politi K,Singh B,Rusch V,Mardis E,Wilson R,Varmus H.EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib..Proc Natl Acad Sci U S A2004;101:13306-11 PMCID:PMC516528

[6] Cancer Genome Atlas Research NetworkComprehensive molecular profiling of lung adenocarcinoma..Nature2014;511:543-50 PMCID:PMC4231481

[7] Schlessinger J.Ligand-induced, receptor-mediated dimerization and activation of EGF receptor..Cell2002;110:669-72

[8] Eck MJ.Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer..Biochim Biophys Acta2010;1804:559-66 PMCID:PMC2859716

[9] Huse M.The conformational plasticity of protein kinases..Cell2002;109:275-82

[10] Kumar A,Halmos B.Structure and clinical relevance of the epidermal growth factor receptor in human cancer..J Clin Oncol2008;26:1742-51 PMCID:PMC3799959

[11] Zhang X,Shen K,Kuriyan J.An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor..Cell2006;125:1137-49

[12] Yarden Y.Untangling the ErbB signalling network..Nat Rev Mol Cell Biol2001;2:127-37

[13] van Lengerich B,Puchner EM,Jura N.EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms..Proc Natl Acad Sci U S A2017;114:E2836-45 PMCID:PMC5389333

[14] Han W.Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations..Cancer Lett2012;318:124-34 PMCID:PMC3304012

[15] Walker F,Gonez LJ,Pouliot N,Burgess AW.Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation..Mol Cell Biol1998;18:7192-204 PMCID:PMC109301

[16] Schnidar H,Klingler S,Kasper M,Regl G,Moriggl R,Aberger F.Epidermal growth factor receptor signaling synergizes with hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway..Cancer Res2009;69:1284-92 PMCID:PMC3035872

[17] Engelman JA,Mermel C,Mukohara T,Cichowski K,Cantley LC.ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines..Proc Natl Acad Sci U S A2005;102:3788-93 PMCID:PMC553328

[18] Park OK,Nathans D.In vitro activation of Stat3 by epidermal growth factor receptor kinase..Proc Natl Acad Sci U S A1996;93:13704-08 PMCID:PMC19397

[19] Anderson D,Grey L,Moran M.Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors..Science1990;250:979-82

[20] Coker KJ,Guyer CA.A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis..Proc Natl Acad Sci U S A1994;91:6967-71 PMCID:PMC44319

[21] Deb TB,Wong L,Wells a,Johnson GR.Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF..J Biol Chem2001;276:15554-60

[22] Weihua Z,Huang WC,Chiu CH,Hung MC.Survival of cancer cells is maintained by EGFR independent of its kinase activity..Cancer Cell2008;13:385-93 PMCID:PMC2413063

[23] Zhu H,Ali-Osman F,Lo HW.EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity..Cancer Lett2010;294:101-10 PMCID:PMC2875288

[24] Irwin ME,Boerner JL.Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells..Cancer Biol Ther2011;12:718-26 PMCID:PMC3218526

[25] Irwin ME,Bohin N,Boerner JL.Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib..J Cell Physiol2011;226:2316-28 PMCID:PMC3103760

[26] Murray S,Linardou H,Bafaloukos D.Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database..J Thorac Oncol2008;3:832-9

[27] Cho J,Sangji N,Yonesaka K,Flavin RJ,Kwon J,Greulich H,Eck MJ,Wong KK.Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization..Cancer Res2013;73:6770-9 PMCID:PMC3903789

[28] Rajasekaran R.In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs..Appl Biochem Biotechnol2010;160:1723-33

[29] Jiang J,Jänne PA,Meyerson M.Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression..Cancer Res2005;65:8968-74

[30] Mok TS,Thongprasert S,Chu D-T,Sunpaweravong P,Margono B,Nishiwaki Y,Yang J-J,Jiang H,Watkins CL,Fukuoka M.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma..N Engl J Med2009;361:947-57

[31] Zhao J,Zhong W,Li L,Nie L,Wang M.Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma..Clin Lung Cancer2013;14:188-93

[32] de Vries NA,Zhao J,Schellens JH.Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP..Invest New Drugs2012;30:443-9

[33] Hoffknecht P1,Wehler T,Wiewrodt R,Serke M,Märten A,Dickgreber NJ.Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease..J Thorac Oncol2015;10:156-63 PMCID:PMC4276567

[34] Solca F,Zoephel A,Sanderson M,Kraemer O,Haaksma E.Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker..J Pharmacol Exp Ther2012;343:342-50

[35] Jin Y,Shi X,Zhang Y,Tong X.Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing..Oncotarget2016;7:61755-63 PMCID:PMC5308688

[36] Engle JA.Afatinib: a first-line treatment for selected patients with metastatic non-small-cell lung cancer..Am J Health Syst Pharm2014;71:1933-8

[37] Lynch TJ,Sordella R,Okimoto RA,Harris PL,Supko JG,Louis DN,Settleman J.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib..N Engl J Med2004;350:2129-39

[38] Paez JG,Lee JC,Greulich H,Herman P,Lindeman N,Naoki K,Fujii Y,Sellers WR,Meyerson M.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy..Science2004;304:1497-500

[39] Yun C-H,Toms A V,Greulich H,Meyerson M.The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP..Proc Natl Acad Sci U S A2008;105:2070-5 PMCID:PMC2538882

[40] Kwak EL,Bell DW,Okimoto RA,Harris PL,Fidias P,Rabindran SK,Wissner A,Isselbacher KJ,Haber DA.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib..Proc Natl Acad Sci2005;102:7665-70 PMCID:PMC1129023

[41] Katakami N,Goto K,Horai T,Ichinose Y,Takeda K,Nishio K,Ebisawa R,Yamamoto N.LUX-lung 4: a phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both..J Clin Oncol2013;31:3335-41

[42] Van Der Steen N,Rolfo C,Peters GJ.New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?.Onco Targets Ther2016;9:6065-74 PMCID:PMC5063481

[43] Cross DAE,Ghiorghiu S,Nebhan CA,Orme JP,Ward RA,Hughes G,Jacobs VN,Ichihara E,Jin H,Al-Kadhimi K,Klinowska T,Cantarini M,Ranson MR.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer..Cancer Discov2014;4:1046-61 PMCID:PMC4315625

[44] Goss G,Shepherd FA,Bazhenova L,de Marinis F,Morabito A,Cantarini M,Mitsudomi T,Yang JC.CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials..Ann Oncol2018;29:687-93

[45] Ballard P,Yang Z,Yang JC,Pickup K,Hickey M,Box M,Varnäs K,Thress KS,Cross D.Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity..Clin Cancer Res2016;22:5130-40

[46] Jänne PA,Kim DW,Ohe Y,Ahn MJ,Su WC,Haggstrom D,Kim JH,Cantarini M,Dickinson PA,Ranson M.AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer..N Engl J Med2015;372:1689-99

[47] Floc’h N,Riess JW,Staniszewska AD,Cuomo ME,Ward RA,McKerrecher D,Vang DP,Keck JG,Mack PC.Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions..Mol Cancer Ther2018; PMCID:PMC5932243

[48] Soria JC,Vansteenkiste J,Chewaskulyong B,Dechaphunkul A,Nogami N,Okamoto I,Cho BC,Cho EK,Planchard D,Gray JE,Hodge R,Rukazenkov Y.Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer..N Engl J Med2018;378:113-25

[49] Mok TS,Ahn M-J,Kim HR,Shepherd FA,Akamatsu H,Lee CK,Templeton A,Marotti M,Papadimitrakopoulou VA.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer..N Engl J Med2017;376:629-40

[50] Mitsudomi T,Bazhenova L,Hida T,Vowler SL,Jänne PA.Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: results from two phase II studies..Ann Oncol2017;28:v460-96

[51] Goss G,Shepherd FA,Lee JS,Crino L,Chu Q,Han JY,Dunphy F,Kang JH,Mann H,Ghiorghiu S.Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study..Lancet Oncol2016;17:1643-52

[52] Passiglia F,Rolfo C.Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?.J Thorac Dis2018;10:S1076-80 PMCID:PMC5949407

[53] Yasuda H,Costa DB.Review EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications..Lancet Oncol2012;13:e23-31

[54] Vanita N,Vijay M. P,Deepa Susan Joy P,Amit D.Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment..Oncotargets2017;10:2903-8 PMCID:PMC5476719

[55] Robichaux JP,Tan Z,Zhang S,Li S,Poteete A,Le AT,Nilsson MB,Roarty E,Brahmer JR,Lu C,Politi K,Wong KK.Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer..Nat Med2018;24:638-46 PMCID:PMC5964608

[56] Romero D.Poziotinib for uncommon ERBB mutations..Nat Rev Clin Oncol2018;15:404

[57] Godin-Heymann N,Brannigan BW,Lamb J,Settleman J.The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor..Mol Cancer Ther2008;7:874-9

[58] Yu HA,Drilon AE,Riely GJ,Ladanyi M.Acquired resistance of egfr-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain..JAMA Oncol2015;1:982-4 PMCID:PMC4665629

[59] Wang S,Liu C,Liu D.EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer..J Hematol Oncol2016;9:59 PMCID:PMC4957905

[60] Yu Z,Kobayashi S,Ma PC,Kern JA,Halmos B.Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies..Cancer Res2007;67:10417-27

[61] Thress KS,Felip E,Stetson D,Lai Z,Vivancos A,Ercan D,Cantarini M,Jänne PA.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M..Nat Med2015;21:560-2 PMCID:PMC4771182

[62] Ercan D,Yun CH,Xie T,Gray NS.EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors..Clin Cancer Res2015;21:3913-23 PMCID:PMC4791951

[63] Balak MN,Riely GJ,Li AR,Chiang A,Ouerfelli O,Ladanyi M,Pao W.Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors..Clin Cancer Res2006;12:6494-501

[64] Bean J,Balak M,Ladanyi M,Pao W.Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma..Clin Cancer Res2008;14:7519-25 PMCID:PMC2596620

[65] Costa DB,Tenen DG.Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations..J Clin Oncol2008;26:1182-4

[66] Zheng D,Bai Y,Lu X,Wang J,Wang Z,Yang Z.EGFR G796D mutation mediates resistance to osimertinib..Oncotarget2017;8:49671-9 PMCID:PMC5564797

[67] Oxnard G,Mileham K,Feeney N,Paweletz C,Jänne P.OA 09.02 osimertinib resistance mediated by loss of EGFR T790M Is associated with early resistance and competing resistance mechanisms..J Thorac Oncol2017;12:S1767-8

[68] Wang S,Liu D.EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance..Cancer Lett2017;385:51-4

[69] Bean J,Shih JY,Viale A,Chitale D,Szoke J,Balak M,Yu CJ,Pass H,Gerald W,Yang PC,Ladanyi M,Pao W.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib..Proc Natl Acad Sci U S A2007;104:20932-7 PMCID:PMC2409244

[70] Cappuzzo F,Skokan M,Rossi E,Zucali PA,Toschi L,Destro A,Alloisio M,Varella-Garcia M.MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients..Ann Oncol2009;20:298-304 PMCID:PMC2733067

[71] Guo A,Kornhauser J,Stokes MP,Possemato A,Innocenti G,Wang Y,Mitchell J,Rush J,Comb MJ.Signaling networks assembled by oncogenic EGFR and c-Met..Proc Natl Acad Sci U S A2008;105:692-7 PMCID:PMC2206598

[72] Shi P,Zhang G,Yue P,Kanteti R,Salgia R,Ramalingam SS,Sun SY.Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment..Cancer Lett2016;380:494-504

[73] Ou SI,Ali SM.High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression..Lung Cancer2016;98:59-61

[74] Minari R,La Monica S,Leonetti A,Azzoni C,Gnetti L,Petronini PG,Tiseo M.Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in a patient with EGFR-mutated NSCLC..J Thorac Oncol2018;13:e89-91

[75] Roberts PJ.KRAS mutation: should we test for it, and does it matter..J Clin Oncol2013;31:1112-21

[76] Pao W,Politi KA,Somwar R,Kris MG.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain..PLoS Med2005;2:e73 PMCID:PMC549606

[77] Linardou H,Kanaloupiti D,Bafaloukos D,Papadimitriou CA.Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer..Lancet Oncol2008;9:962-72

[78] Eberlein CA,Markovets AA,Lai Z,Meador CB,Ichihara E,Ahdesmaki MJ,Ratcliffe LE,Barnes CH,Smith PD,Beran G,Dougherty B,Cross DA.Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models..Cancer Res2015;75:2489-500 PMCID:PMC4605607

[79] Zhang Z,Lin L,Au V,Abdel-Rahman M,Levine AD,Choi YJ,Kim SW,Park YS,Lee DH,Miller VA,Ladanyi M,Sawyers C,Ma PC,Taron M,Halmos B.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer..Nat Genet2012;44:852-60 PMCID:PMC3408577

[80] Wu F,Jang C,Xiong J.The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma..Int J Clin Exp Pathol2014;7:6653-61 PMCID:PMC4230140

[81] Tian Y,Miao L,Yang J,Qian D,Wang Y.Anexelekto (AXL) increases resistance to EGFR-TKI and activation of AKT and ERK1/2 in non-small cell lung cancer cells..Oncol Res2016;24:295-303

[82] Moasser MM,Averbuch SD.The tyrosine kinase inhibitor ZD1839 (“ Iressa ”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells..Cancer Res2001;61:7184-8

[83] Varella-Garcia M,Yatabe Y,Nakajima E,Skokan M,Franklin WA,Hirsch FR.EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort..J Thorac Oncol2009;4:318-25 PMCID:PMC3379811

[84] Cappuzzo F,Shigematsu H,Bartolini S,Rossi E,Gregorc V,Franklin WA,Gazdar AF,Hirsch FR.Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients..J Clin Oncol2005;23:5007-18

[85] Takezawa K,Arcila ME,Song X,Ohashi K,Spitzler PJ,Riely GJ,Miller VA,Politi K.HER2 amplification: a potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation..Cancer Discov2012;2:922-33 PMCID:PMC3473100

[86] Wang SE,Perez-Torres M,Wu FY,Carpenter G,Muthuswamy SK.HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors..Cancer Cell2006;10:25-38

[87] Ou SI,Bocharov EV,Haddad CK,Johnson M,Chung J,Ross JS,Miller VA,Ali SM.HER2 transmembrane domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib..J Thorac Oncol2017;12:446-57

[88] Liu S,Hai J,Chen T,Gao P,Ji H,Wong KK.Targeting HER2 aberrations in non-small cell lung cancer with osimertinib..Clin Cancer Res2018;24:2594-604

[89] Landi L,Chiari R,Rossi E,Novello S,D’Incecco A,Tibaldi C,Facchinetti F,Cortinovis D,Banna G,GiajLevra M,de Marinis F.Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors..Clin Lung Cancer2014;15:411-7

[90] Yonesaka K,Okamoto I,Cappuzzo F,Ercan D,Roncalli M,Fujisaka Y,Shimizu T,Cho Y,Destro A,Takeda K,Swanson J,Takada M,Okuno K,Shivdasani RA,Fukuoka M,Nakagawa K.Activation of ERBB2 signaling causes resistance to the EGFR- directed therapeutic antibody cetuximab..Sci Transl Med2011;3:99ra86 PMCID:PMC3268675

[91] Vazquez-Martin A,Oliveras-Ferraros C,Corominas-Faja B,Bonavia R,Martin-Castillo B,Micol V,Menendez JA.IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations..Sci Rep2013;3:2560 PMCID:PMC3759044

[92] Morgillo F,Kim ES,Lee HY.Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib..Cancer Res2006;66:10100-11

[93] Morgillo F,Kim ES,Hong WK.Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib..Clin Cancer Res2007;13:2795-803

[94] Lee Y,James M,You M.Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells..Mol Carcinog2016;55:991-1001 PMCID:PMC6003619

[95] Park JH,Kim SY,Sung KJ,Kim WS,Choi CM,Rho JK.Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer..Oncotarget2016;7:22005-15 PMCID:PMC5008340

[96] Choi YJ,Jeon BS,Park SC,Kim HR,Lee JC.Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors..Cancer Chemother Pharmacol2010;66:381-8

[97] Hurbin A,Busser B,Tenaud C,Dufort S,Moro-Sibilot D,Coll JL.Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma..J Pathol2011;225:8395

[98] Kono SA,Ware KE.The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer..Drug Resist Updat2009;12:95-102 PMCID:PMC2763047

[99] Marek L,Fritzsche A,Helton WR,McDermott LA,Nemenoff RA,Helfrich BA,Heasley LE.Fibroblast growth factor ( FGF ) and FGF receptor-mediated autocrine signaling in non – small-cell lung cancer cells..Mol Pharmacol2009;75:196-207 PMCID:PMC2669785

[100] Thomson S,Sujka-Kwok I,Haley JD.Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy..Clin Exp Metastasis2008;25:843-54

[101] Ware KE,Heasley LR,Hinz TK,Helfrich BA,Heasley LE.Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression..PLoS One2010;5:e14117 PMCID:PMC2994708

[102] Terai H,Yasuda H,Hamamoto J,Ishioka K,Ikemura S,Yoda S,Naoki K.Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC..Mol Cancer Res2013;11:759-67

[103] Azuma K,Sonoda K,Tashiro K,Izumi H,Kuwano M,Hoshino T.FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor..Oncotarget2014;5:5908-19 PMCID:PMC4171601

[104] Yamamoto H,Nomura M,Sato M,Soh J,Wistuba II,Lee H,Date H,Minna JD.PIK3CA mutations and copy number gains in human lung cancers..Cancer Res2008;68:6913-21 PMCID:PMC2874836

[105] Ludovini V,Pistola L,Minotti V,Giuffrida D,Siggillino A,Baldelli E,Mameli MG,Crinò L.Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer..J Thorac Oncol2011;6:707-15

[106] VanderLaan PA,Mockus SM,Reddi HV,Huberman MS,Kobayashi SS.Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes..Lung Cancer2017;106:17-21 PMCID:PMC5351777

[107] Fidler MJ,Basu S,Walters K,Jacobson KK,Coon J4th.PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy..Br J Cancer2011;105:1920-6 PMCID:PMC3251891

[108] Martín Martorell P,Compañ Quilis A,Seda E,Chaves FJ,Roselló Keränen S,Insa A.Coexistence of EGFR, KRAS, BRAF, and PIK3CA mutations and ALK rearrangement in a comprehensive cohort of 326 consecutive Spanish nonsquamous NSCLC patients..Clin Lung Cancer2017;18:e395-402

[109] Leonetti A,Rossi G,Conti A,Tiseo M.BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall..Cancer Treat Rev2018;66:82-94

[110] Marchetti A,Malatesta S,Guetti L,Viola P,Mucilli F.Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations..J Clin Oncol2011;29:3574-9

[111] Ohashi K,Arcila ME,Chmielecki J,Pan Y,de Stanchina E,Aoe K,Kiura K,Fidias P,Miller VA,Kris MG,Vnencak-Jones CL,Ladanyi M.Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1..Proc Natl Acad Sci2012;109:E2127-33 PMCID:PMC3411967

[112] Lin L,Chan E,Martins MM,Yan JJ,Wang MM,Solit DB,Rudin CM,Bivona TG.Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer..Proc Natl Acad Sci U S A2014;111:E748-57 PMCID:PMC3932924

[113] Ho CC,Lin CA,Yu CJ.Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib..J Thorac Oncol2017;12:567-72

[114] Yamamoto C,Kawahara A,Kage M,Kohno K,Yasumoto K,Ono M.Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations..Cancer Res2010;70:8715-25

[115] Sos ML,Weir BA,Rabinovsky R,Seeger JM,Fischer F,Michel K,Mermel C,Peyton M,Minna JD,Kashkar H,Meyerson M.PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR..Cancer Res2009;69:3256-61 PMCID:PMC2849653

[116] Kokubo Y,Noro R,Kataoka K,Okano T,Yoshimura A,Kudoh S.Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)..Br J Cancer2005;92:1711-9 PMCID:PMC2362053

[117] Shepherd FA,Le Teuff G,Jänne PA,Le Chevalier T,Douillard JY,Brambilla E,Filipits M,Soria JC.Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non–small-cell lung cancer in four trials of adjuvant chemotherapy..J Clin Oncol2017;35:2018-27 PMCID:PMC6075828

[118] Canale M,Delmonte A,Dazzi C,Capelli L,De Luigi N,Gamboni A,Bennati C,Ludovini V,Amadori D.Impact of TP53 mutations on outcome in EGFR -mutated patients treated with first-line tyrosine kinase inhibitors..Clin Cancer Res2017;23:2195-202

[119] Labbé C,Korpanty GJ,Doherty MK,Jao K,Wang R,Leighl NB,Liu G,Kamel-Reid S,Shepherd FA.Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)..Lung Cancer2017;111:23-9

[120] You B,Xu Z,Liu S,Tetsu O,Jablons DM.Inhibition of ERK1/2 down-regulates the hippo/YAP signaling pathway in human NSCLC cells..Oncotarget2015;6:4357-68 PMCID:PMC4414195

[121] McGowan M,Halvorsen AR,Brustugun OT.NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors..Genes Cancer2017;8:497-504 PMCID:PMC5489647

[122] Hsu PC,Yang YL,Wang YC,Dai Y,Yang CT,Hu B,You L.YAP promotes erlotinib resistance in human non-small cell lung cancer cells..Oncotarget2016;7:51922-33 PMCID:PMC5239524

[123] Ghiso E,Ciciriello V,Petrelli A,De Luca E,Volante M.YAP-dependent AXL overexpression mediates resistance to EGFR inhibitors in NSCLC..Neoplasia2017;19:1012 PMCID:PMC5683041

[124] Galvani E,Leon LG,Narayan RS,Lee K,Heideman DA,Heynen GJ,Smit EF,Peters GJ.NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor..Oncotarget2015;6:42717-32 PMCID:PMC4767465

[125] Voortman J,Giaccone G.The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells..Mol Cancer2007;6:73 PMCID:PMC2194734

[126] Voortman J,Knol JC,Jimenez CR.Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling..Proteome Sci2009;7:34 PMCID:PMC2746186

[127] Ceresa C,Voortman J,Honeywell R,Peters GJ.Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells..Mol Cancer Ther2009;8:1026-36

[128] Sequist LV,Dias-Santagata D,Turke AB,Bergethon K,Gettinger S,Akhavanfard S,Temel J,Wain JC,Vernovsky K,Lanuti M,Mino-Kenudson M.Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors..Sci Transl Med2011;3:75ra26 PMCID:PMC3132801

[129] Zakowski MF,Kris MG.EGFR mutations in small-cell lung cancers..N Engl J Med2006;355:213-5

[130] Oser MG,Sequist LV.Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin..Lancet Oncol2015;16:e165-72 PMCID:PMC4470698

[131] Lee JK,Kim S,Youk J,An Y,Kim DW,Kim YT,Kim SH,Lee SH,Ku JL,Chung DH,Kim J,Ju YS.Clonal history & genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas..J Clin Oncol2017;35:3065-74

[132] Niederst MJ,Poirier JT,Lockerman EL,Katayama R,Ross KN,Howe E,Mulvey HE,Mohamoud F,VanderLaan PA,Jänne PA,Ramaswamy S,Iafrate AJ,Rudin CM,Engelman JA.RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer..Nat Commun2015;6:6377 PMCID:PMC4357281

[133] Lemos C,Peters GJ.Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors..Br J Cancer2008;98:857-62 PMCID:PMC2266858

[134] Da Silva CG,Dekker H.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters..Expert Opin Drug Metab Toxicol2015;11:703-17

[135] Porcelli L,Peters GJ,Azzariti A.Intracellular trafficking of MDR transporters and relevance of SNPs..Curr Top Med Chem2009;9:197-208

[136] Elkind NB,Apáti A,Várady G,Szabó K,Váradi A,Kéri G,Sarkadi B.Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor iressa (ZD1839, Gefitinib ) multidrug transporter ABCG2 prevents tumor cell death induced..Cancer Res2005;65:1770-7

[137] Brózik A,Erdei Z,Özvegy-Laczka C,Sarkadi B.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?.Expert Opin Drug Metab Toxicol2011;7:623-42

[138] Yanase K,Asada S,Imai Y.Gefitinib reverses breast cancer resistance protein-mediated drug resistance..Mol Cancer Ther2004;3:1119-25

[139] Nakamura Y,Soda H,Yoshikawa M,Ikegami Y,Nakatomi K,Doi S,Kohno S.Gefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance..Cancer Res2005;65:1541-6

[140] Marchetti S,Buckle T,van Eijndhoven MA,Mazzanti R,Schellens JH.Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice..Mol Cancer Ther2008;7:2280-7

[141] Lemos C,Giovannetti E,Jansen G.Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib..Br J Cancer2009;100:1120-7 PMCID:PMC2669988

[142] Wind S,Ebner T,Stopfer P.Clinical pharmacokinetics and pharmacodynamics of afatinib..Clin Pharmacokinet2017;56:235-50 PMCID:PMC5315738

[143] Kazmi F,Pope C,Loewen GJ,Parkinson A.Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells)..Drug Metab Dispos2013;41:897-905 PMCID:PMC3608459

[144] Nadanaciva S,Gebhard DF,Pennie WD.A high content screening assay for identifying lysosomotropic compounds..Toxicol Vitr2011;25:715-23

[145] Zhitomirsky B.Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance..Oncotarget2015;6:1143-56 PMCID:PMC4359223

[146] Honeywell R,Giovannetti E,Smit EF,Lind JS,Verheul HM.Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry..J Chromatogr B Anal Technol Biomed Life Sci2010;878:1059-68

[147] Van Der Steen N,Dekker H,Kole J,Ruijtenbeek R,Pauwels P,Giovannetti E.Resistance to crizotinib in a cMET gene amplified tumor cell line is associated with impaired sequestration of crizotinib in lysosomes..J Mol Clin Med2018;1:101-8

[148] Gotink KJ,Labots M,Dekker H,Rudek MA,Musters RJ,Griffioen AW,Pili R,Verheul HM.Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance..Clin Cancer Res2011;17:7337-46 PMCID:PMC4461037

[149] Gotink KJ,de Haas RR,Dekker H,Azijli K,Broxterman HJ.Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib..Cell Oncol (Dordr)2015;38:119-29 PMCID:PMC4555235

[150] Zhitomirsky B.Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis..Oncotarget2017;8:45117-32 PMCID:PMC5542171

[151] Honeywell RJ,Kathmann I.Transport of six tyrosine kinase inhibitors: active or passive?.2016;4:23-34

[152] Galvani E,Giovannetti E.Thymidylate synthase inhibitors for non-small cell lung cancer..Expert Opin Investig Drugs2011;20:1343-56

[153] Rolfo C,Santarpia M,Giovannetti E,Pauwels P.Immunotherapy in NSCLC: a promising and revolutionary weapon..Adv Exp Med Biol2017;995:97-125

[154] Avan A,Giovannetti E.Role of Akt signaling in resistance to DNA-targeted therapy..World J Clin Oncol2016;7:352-69 PMCID:PMC5056327

[155] Giovannetti E,Tekle C,Nannizzi S,Ricciardi S,Giaccone G.Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells..Mol Pharmacol2008;73:1290-300

[156] Avan A,Hoebe EK,Avan A,Ruijtenbeek R,Peters GJ.Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib..Curr Drug Targets2014;15:1312-21

[157] Narayan RS,Brands E,Stalpers LJ,Slotman BJ,Peters GJ.The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures..BMC Cancer2017;17:204 PMCID:PMC5359921